Rapamune (sirolimus) 1 mg tablets, 100 tablets — original (Pfizer, Italy) Rapamune is intended for the prevention of transplant rejection. Drug delivery from Europe, storage conditions observed, payment upon receipt +380996042415 Viber, WhatsApp.

Rapamune is intended for oral administration only.

It is not recommended to break the tablets before swallowing them, as the bioavailability of the drug after crushing, chewing, or breaking the tablets has not been studied.

Patients unable to take Rapamune in tablet form should receive it as an oral solution.

Rapamune should be taken continuously, either with or between meals.

Therapy should be carried out in a specially equipped under the supervision of a transplant surgeon.

It is recommended to take Rapamune 4 hours after taking cyclosporine microemulsion.

Adults

Initial therapy (for 2-3 months after transplant): As a standard regimen, a single loading dose of 6 mg of Rapamune is administered orally as soon as possible after transplantation, followed by a dose of 2 mg once daily. Subsequently, the dose of Rapamune is individually adjusted to achieve trough blood concentrations of 4 to 12 ng/ml (chromatographic method). Treatment with Rapamune is continued while gradually tapering the dose of glucocorticosteroids and cyclosporine microemulsion.

During the first 2-3 months after transplantation, cyclosporine trough concentrations are recommended to be maintained within the range of 150-400 ng/ml (immune assay).

Maintenance therapy: 4-8 weeks after initiating cyclosporine treatment, its dose should be gradually reduced until the drug is completely discontinued, and the dose of Rapamune should be adjusted so that trough blood concentrations range from 12 to 20 ng/ml (chromatographic assay). Rapamune should be administered in combination with glucocorticosteroids. In patients in whom cyclosporine discontinuation is unsuccessful or impossible, the duration of combined therapy with cyclosporine and Rapamune should not exceed 3 months. In clinically appropriate situations, such patients should be discontinued from Rapamune and given an alternative immunosuppressive regimen.